# CDSCO Type: organization Source: GetYourBrief — https://getyourbrief.com/entity/cdsco Canonical HTML page: https://getyourbrief.com/entity/cdsco ## Timeline - **2027-01-01**: Implementation Phase — Expected start of streamlined registration for priority therapeutic categories. - **2026-06-15**: Technical Working Group (Projected) — First meeting of regulatory experts to define GMP inspection sharing protocols. - **2026-Q2 (projected)**: Prescription Crackdown — Expected implementation of stricter digital prescription tracking for GLP-1 medications. - **2026-03-24**: Regulatory Warning — India's CDSCO issues a formal alert regarding the misuse of affordable weight-loss jabs. - **2026-03-15T05:15:42Z**: — Government expands Production Linked Incentives for high-end medical hardware. - **2026-03-15T05:15:42Z**: — Department of Commerce holds strategic session to strengthen the export ecosystem. - **2026-02-22**: Bilateral Briefing — Government representatives outline the scope of pharmaceutical and medical product alignment. - **2026-02-22**: Formal Announcement — Official confirmation of the bilateral agreement to strengthen medical product regulation. - **2026-02-21**: MoU Exchange — Official documents exchanged between India and Brazil to initiate regulatory cooperation. - **2026-02-21**: MoU Exchange Initiated — Initial diplomatic exchange of the regulatory cooperation framework in New Delhi. - **2025-Q2**: Generic Entry — Indian pharmaceutical firms begin ramping up production of low-cost semaglutide biosimilars. - **2024-Q4**: Global Shortages — High demand for GLP-1 drugs in Western markets leads to global supply constraints. - **2023-04-26**: National Medical Device Policy — Union Cabinet approves policy to facilitate orderly growth of the medical device sector. ## Recent coverage (7 stories, network-wide) ### India Issues Regulatory Warning Over Misuse of Low-Cost Weight-Loss Injectables 2026-03-24 15:10:54 · Sector: bio · Sentiment: Negative · Impact: 6/10 · Sources: 2 Indian health authorities have issued a formal warning regarding the rising misuse and health risks associated with affordable, non-regulated weight-loss injections. The move signals a tightening of oversight as the global demand for GLP-1 therapies triggers a surge in local compounding and unauthorized distribution. Full story: https://getbiobrief.com/story/india-weight-loss-jab-warning-2026 ### India Issues Regulatory Alert Over Misuse of Low-Cost GLP-1 Weight-Loss Jabs 2026-03-24 15:07:58 · Sector: health · Sentiment: Negative · Impact: 6/10 · Sources: 2 Indian health authorities have issued a formal warning regarding the rising misuse of affordable weight-loss injections, highlighting risks associated with unsupervised administration. As the domestic market for GLP-1 receptor agonists expands, regulators are moving to curb off-label cosmetic use that threatens public health and drug availability for diabetic patients. Full story: https://gethealthbrief.com/story/india-weight-loss-jab-misuse-warning ### India Targets Global MedTech Leadership via Strategic Chintan Shivir 2026-03-15 05:15:42 · Sector: bio · Sentiment: Positive · Impact: 6/10 · Sources: 4 The Indian Department of Commerce has convened a high-level Chintan Shivir to overhaul the nation's medical device export ecosystem. The initiative seeks to streamline regulatory frameworks and position India as a primary global manufacturing hub for high-end medical technology. Full story: https://getbiobrief.com/story/india-medical-device-export-strategy-chintan-shivir ### AIOCD Opposes Drug Licenses for Primary Agricultural Credit Societies (PACS) 2026-03-06 06:53:49 · Sector: health · Sentiment: Negative · Impact: 6/10 · Sources: 2 The All India Organisation of Chemists and Druggists (AIOCD) has launched a formal protest against a government proposal to allow Primary Agricultural Credit Societies (PACS) to operate pharmacies. The AIOCD argues that these cooperative societies lack the technical expertise and infrastructure required to safely dispense medications, potentially endangering public health. Full story: https://gethealthbrief.com/story/aiocd-opposes-pacs-drug-licenses-india ### AIOCD Challenges Proposal to Grant Drug Licenses to Agricultural Societies 2026-03-06 06:53:45 · Sector: legal · Sentiment: Negative · Impact: 6/10 · Sources: 2 The All India Organisation of Chemists and Druggists (AIOCD) has launched a formal opposition against a government proposal to grant drug licenses to Primary Agricultural Credit Societies (PACS). The trade body argues that allowing non-specialized cooperative societies to dispense medication poses a severe risk to public health and undermines existing pharmaceutical regulations. Full story: https://getlegalbrief.com/story/aiocd-opposes-pacs-drug-licensing ### India and Brazil Ink Strategic Regulatory Pact for Pharma and MedTech 2026-02-22 12:33:22 · Sector: bio · Sentiment: Positive · Impact: 6/10 · Sources: 2 India and Brazil have formalized a Memorandum of Understanding (MoU) to harmonize regulatory standards for pharmaceutical and medical products. This bilateral agreement aims to streamline market access and enhance technical cooperation between two of the world's most influential emerging healthcare markets. Full story: https://getbiobrief.com/story/india-brazil-pharma-regulatory-mou-2026 ### India and Brazil Ink Regulatory Pact to Streamline Pharma and MedTech Trade 2026-02-22 12:32:48 · Sector: health · Sentiment: Positive · Impact: 6/10 · Sources: 2 India and Brazil have formalized a Memorandum of Understanding (MoU) to harmonize the regulation of pharmaceutical and medical products. This strategic partnership aims to enhance bilateral cooperation, streamline market entry for life sciences companies, and ensure the safety and efficacy of medical goods exchanged between the two major emerging economies. Full story: https://gethealthbrief.com/story/india-brazil-pharma-regulatory-mou-2026 --- This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.